Document is current
Any future updates will be listed below
-
Authors
,
Naganuma, Makoto http://orcid.org/0000-0002-4244-3243
Yokoyama, Yoko
Motoya, Satoshi
Watanabe, Kenji
Sawada, Koji
Hirai, Fumito
Yamamoto, Takayuki
Hanai, Hiroyuki
Omori, Teppei
Kanai, Takanori
Hibi, Toshifumi
-
Funding
Funding for this research was provided by:
JIMRO Co., Ltd (non-financial support)
Asahi Kasei Pharma Corporation (non-financial support)
- License Information
-
More Information
Article History
Received: 29 August 2019
Accepted: 26 November 2019
First Online: 6 December 2019
Compliance with ethical standards
:
: Makoto Naganuma received commercial research funds from EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd., outside the submitted work. Satoshi Motoya received consultant fees from Abbvie GK, Janssen Pharmaceutical K.K, Kyorin Pharmaceutical Co. Ltd, and Pfizer Japan Inc. and received lecture fees from Takeda Pharmaceutical Co., Ltd., Abbvie GK, Janssen Pharmaceutical K.K, Mistubishi Tanabe Pharma, and Mochida Pharmaceutical Co., Ltd., outside the submitted work. Fumihito Hirai received lecture fees from Abbvie GK, EA Pharma Co., Ltd, Mistubishi Tanabe Pharma, Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. Takanori Kanai received lecture fees from Mitsubishi Tanabe Pharma Corp, Astellas Pharma Inc, Miyarisan Pharmaceutical Co., Ltd. AstraZeneca Plc, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd. and commercial research funds from AbbVie GK,Mochida Pharmaceutical Co., Ltd.,Kyorin Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp, Takeda Pharmaceutical Co., Ltd., Nihon Kayaku, Yakult Honsha Co., Ltd.,Zeria Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Ezaki Glico Co., Ltd., JIMRO Co., Ltd. and EN Otsuka Pharmaceutical Co., Ltd, outside the submitted work. Toshifumi Hibi received lecture fees from Mitsubishi Tanabe Pharma Corp, Abbvie GK, EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Gilead Sciences Celltrion, Nihon Kayaku, Zeria Pharmaceutical Co., Ferring Pharmaceutical, Lilly Co., Ltd., Pfizer Japan Inc. outside the submitted work. All other authors have no competing interests to declare.
